Loading...

Hideho Okada, MD, PhD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentNeurological Surgery
Address1450 3rd Street
San Francisco CA 94158
Phone415-476-1637
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Nagoya University M.D.1991School of Medicine
    Nagoya University Ph.D.1996School of Medicine
    Collapse Awards and Honors
    Uehara Memorial Foundation 1996  - 1997Postdoctoral Scholarship
    Doris Duke Charitable Foundation 2001  - 2006Clinical Scientist Development Award
    James S. McDonnell’s Foundation2003  - 200721st Century Scientist Award
    Journal of Translational Medicine2006  - 2007Excellence in Translational Medicine Award
    University of Pittsburgh 2008Innovator Award
    University of Pittsburgh2009Faculty Honoree at the Annual Convocation
    American Society for Clinical Investigation (ASCI)2010Selected to be a Member
    Society for Immunotherapy for Cancer 2010Team Science Recognition Award
    University of Pittsburgh2011Faculty Honoree at the Annual Convocation
    University of Pittsburgh 2012Innovator Award
    University of Pittsburgh2013Faculty Honoree at the Annual Convocation
    University of Pittsburgh2014Faculty Honoree at the Annual Convocation

    Collapse Overview 
    Collapse Overview
    Dr. Okada is a creative physician-scientist who has developed therapeutic modalities in the laboratory, translated them into clinical protocols, and used his expertise as both scientist and clinician to assess the clinical data from ongoing trials. Dr. Okada's work has consistently focused on immunotherapeutic strategies aimed at a daunting challenge in oncology – malignant brain tumors. Dr. Okada conducted one of the first immune gene therapy trials in patients with malignant glioma. Dr. Okada's success in navigating the detailed regulatory processes that such trials require demonstrates his attention to detail and breadth of knowledge from basic science to clinical care. Dr. Okada's lab work was the first to identify and fully characterize cytotoxic T-lymphocyte (CTL) epitopes for gliomas. Dr. Okada's seminal discovery of CTL epitopes in glioma-associated antigens and the work on the mechanisms underlying the adjuvant effects of poly-ICLC enabled him to launch novel glioma vaccine trials in combination with poly-ICLC as an adjuvant. These efforts have also been supported by his mechanistic studies delineating the role of an integrin receptor very late activation antigen (VLA)-4 and chemokine CXCL10 in efficient trafficking of T-cells to brain tumor sites. Dr. Okada has held 4 Investigational New Drug approvals for his own vaccine trials. Since 2004 to 2014, Dr. Okada served as a Co-Leader of the Brain Tumor Program within the University of Pittsburgh Cancer Institute and has worked to expand the program by developing strong interdisciplinary and translational research activities among program members. In 2010, Dr. Okada was selected to be a member of the American Society for Clinical Investigation, which is an honor society of physician-scientists, those who translate findings in the laboratory to the advancement of clinical practice.


    Collapse Research 
    Collapse Research Activities and Funding
    Novel K27M Mutation-derived Neoantigen for T Cell Therapy in Gliomas
    NIH/NINDS R01NS096954May 15, 2016 - Mar 31, 2021
    Role: Principal Investigator
    Antigens for Molecularly Targeted Vaccines for Progressive Glioma
    NIH/NINDS R21NS093654Jul 1, 2015 - Jun 30, 2017
    Role: Principal Investigator
    Phase I Vaccine Study using Brain Tumor Initiating Cells in WHO Grade II Gliomas
    NIH/NCI R21CA177787Sep 25, 2014 - Aug 31, 2016
    Role: Principal Investigator
    Novel adoptive transfer therapy for glioma using CAR-transduced Type17 T-cells
    NIH/NINDS R21NS083171Sep 15, 2014 - Aug 31, 2016
    Role: Principal Investigator
    Peptide-Based Vaccine Therapy for Childhood Malignant Gliomas
    NIH/NCI R21CA149872Mar 1, 2010 - Feb 28, 2013
    Role: Co-Principal Investigator
    A Bi-Institutional Pilot Study of Vaccinations for Patients with Low Grade Glioma
    NIH/NCI R21CA133859Jul 1, 2009 - Jun 30, 2012
    Role: Principal Investigator
    Directing Tumor-specific T cells to Tumors
    NIH P01CA132714Apr 27, 2009 - Mar 31, 2014
    Role: Co-Investigator
    Vaccination With Peptide-loaded alphaDC1s For Malignant Gliomas
    NIH/NCI R21CA117152Jan 1, 2007 - Dec 31, 2009
    Role: Principal Investigator
    Novel Immunotherapy of Glioma using miR-17-92 Transfected T Cells
    NIH/NINDS R01NS055140Apr 1, 2006 - Jan 31, 2016
    Role: Principal Investigator
    Cytokine Gene Therapy of Cancer - Preclinical Studies
    NIH P01CA100327May 23, 2005 - Mar 31, 2011
    Role: Co-Investigator
    Novel Strategies for Brain Tumor Therapy
    NIH P01NS040923Dec 1, 2000 - Feb 28, 2014
    Role: Co-Investigator
    General Clinical Research Center
    NIH M01RR000056Dec 1, 1978 - Mar 31, 2009
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017 Jul 19; 9(399). PMID: 28724573.
      View in: PubMed
    2. Okada H, Thorne SH. Is the immune response a friend or foe for viral therapy of glioma? Neuro Oncol. 2017 Jul 01; 19(7):882-883. PMID: 28874006.
      View in: PubMed
    3. Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, Warta R, Amankulor NA, Herold-Mende C, Costello JF, Okada H. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017 Apr 03; 127(4):1425-1437. PMID: 28319047.
      View in: PubMed
    4. Castro BA, Flanigan P, Jahangiri A, Hoffman D, Chen W, Kuang R, De Lay M, Yagnik G, Wagner JR, Mascharak S, Sidorov M, Shrivastav S, Kohanbash G, Okada H, Aghi MK. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene. 2017 Jun 29; 36(26):3749-3759. PMID: 28218903.
      View in: PubMed
    5. Furtado AD, Ceschin R, Blüml S, Mason G, Jakacki RI, Okada H, Pollack IF, Panigrahy A. Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience. Neuroimaging Clin N Am. 2017 Feb; 27(1):155-166. PMID: 27889021.
      View in: PubMed
    6. Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol. 2016 Dec; 130(3):517-527. PMID: 27624914.
      View in: PubMed
    7. Han SJ, Reis G, Kohanbash G, Shrivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, Perry A, Okada H. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. J Neurooncol. 2016 Dec; 130(3):543-552. PMID: 27624915.
      View in: PubMed
    8. Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, Ronen SM. Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine. Sci Rep. 2016 Aug 10; 6:31397. PMID: 27507680; PMCID: PMC4979036.
    9. Lin Y, Okada H. Cellular immunotherapy for malignant gliomas. Expert Opin Biol Ther. 2016 Oct; 16(10):1265-75. PMID: 27434205.
      View in: PubMed
    10. Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, Choi J, Chan T, Okada H, Lotze M, Grandi P, Amankulor N. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro Oncol. 2016 Oct; 18(10):1402-12. PMID: 27116977; PMCID: PMC5035522 [Available on 10/01/17].
    11. Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Normolle DP, Connelly AK, Dibridge S, Mason G, Whiteside TL, Okada H. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro Oncol. 2016 Aug; 18(8):1157-68. PMID: 26984745; PMCID: PMC4933485 [Available on 08/01/17].
    12. Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Jun; 5(6):e1145332. PMID: 27471611; PMCID: PMC4938323 [Available on 02/18/17].
    13. Sloan AE, Okada H, Ryken TC, Kalkanis SN, Olson JJ. The role of emerging therapy in the management of patients with diffuse low grade glioma. J Neurooncol. 2015 Dec; 125(3):631-5. PMID: 26530260.
      View in: PubMed
    14. Dunn GP, Okada H. Principles of immunology and its nuances in the central nervous system. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii3-vii8. PMID: 26516224; PMCID: PMC4625893 [Available on 11/01/16].
    15. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-42. PMID: 26545842; PMCID: PMC4638131 [Available on 11/01/16].
    16. Ahn B, Kohanbash G, Ohkuri T, Kosaka A, Chen X, Ikeura M, Wang TC, Okada H. Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas. Oncoimmunology. 2015 Nov; 4(11):e1047581. PMID: 26451324.
      View in: PubMed
    17. Muller L, Muller-Haegele S, Mitsuhashi M, Gooding W, Okada H, Whiteside TL. Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. Oncoimmunology. 2015 Jun; 4(6):e1008347. PMID: 26155415.
      View in: PubMed
    18. Reardon DA, Okada H. Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J Neurooncol. 2015 Jul; 123(3):339-46. PMID: 25707876.
      View in: PubMed
    19. Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD, Engels B, Singh R, Ezell T, Idamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykora JT, Okada H, June CH, Brogdon JL, Maus MV. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015 Feb 18; 7(275):275ra22. PMID: 25696001; PMCID: PMC4467166.
    20. Kosaka A, Ohkuri T, Ikeura M, Kohanbash G, Okada H. Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. Biochem Biophys Res Commun. 2015 Mar 13; 458(3):549-54. PMID: 25677619; PMCID: PMC4355048.
    21. Ohkuri T, Ghosh A, Kosaka A, Sarkar SN, Okada H. Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy. Oncoimmunology. 2015 Apr; 4(4):e999523. PMID: 26137417.
      View in: PubMed
    22. Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fucíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Classification of current anticancer immunotherapies. Oncotarget. 2014 Dec 30; 5(24):12472-508. PMID: 25537519; PMCID: PMC4350348.
    23. Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, Okada H, Donson AM, Foreman NK, Hunt MA, Pennell CA, Olin MR. CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. J Immunother Cancer. 2014; 2(1):46. PMID: 25598973; PMCID: PMC4296547.
    24. Okada H, Butterfield LH, Hamilton RL, Hoji A, Sakaki M, Ahn BJ, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively MO, Chan MD, Salazar AM, Shaw EG, Potter DM, Lieberman FS. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res. 2015 Jan 15; 21(2):286-94. PMID: 25424847; PMCID: PMC4297523.
    25. Ohkuri T, Ghosh A, Kosaka A, Zhu J, Ikeura M, David M, Watkins SC, Sarkar SN, Okada H. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res. 2014 Dec; 2(12):1199-208. PMID: 25300859; PMCID: PMC4258479.
    26. Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, Potter DM, Connelly AK, Dibridge SA, Whiteside TL, Okada H. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014 Jul 01; 32(19):2050-8. PMID: 24888813; PMCID: PMC4067943.
    27. Kosaka A, Ohkuri T, Okada H. Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunol Immunother. 2014 Aug; 63(8):847-57. PMID: 24878890; PMCID: PMC4221287.
    28. Ohno M, Ohkuri T, Kosaka A, Tanahashi K, June CH, Natsume A, Okada H. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. J Immunother Cancer. 2013; 1:21. PMID: 24829757; PMCID: PMC4019893.
    29. Ahn BJ, Pollack IF, Okada H. Immune-checkpoint blockade and active immunotherapy for glioma. Cancers (Basel). 2013 Nov 01; 5(4):1379-412. PMID: 24202450; PMCID: PMC3875944.
    30. Pollack IF, Jakacki RI, Butterfield LH, Okada H. Ependymomas: development of immunotherapeutic strategies. Expert Rev Neurother. 2013 Oct; 13(10):1089-98. PMID: 24117271; PMCID: PMC3972122.
    31. Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N, Fujita M, Ohlfest JR, Okada H. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-a. Cancer Res. 2013 Nov 01; 73(21):6413-23. PMID: 24030977; PMCID: PMC3829000.
    32. Pollack IF, Jakacki RI, Butterfield LH, Okada H. Peptide vaccine therapy for childhood gliomas. Neurosurgery. 2013 Aug; 60 Suppl 1:113-9. PMID: 23839362.
      View in: PubMed
    33. Zhong J, Sakaki M, Okada H, Ahrens ET. In vivo intracellular oxygen dynamics in murine brain glioma and immunotherapeutic response of cytotoxic T cells observed by fluorine-19 magnetic resonance imaging. PLoS One. 2013; 8(5):e59479. PMID: 23667419; PMCID: PMC3648573.
    34. Okada H, Scheurer ME, Sarkar SN, Bondy ML. Integration of epidemiology, immunobiology, and translational research for brain tumors. Ann N Y Acad Sci. 2013 May; 1284:17-23. PMID: 23651189; PMCID: PMC3648859.
    35. Liu Y, Kosaka A, Ikeura M, Kohanbash G, Fellows-Mayle W, Snyder LA, Okada H. Premetastatic soil and prevention of breast cancer brain metastasis. Neuro Oncol. 2013 Jul; 15(7):891-903. PMID: 23595625; PMCID: PMC3688013.
    36. Yeung JT, Hamilton RL, Ohnishi K, Ikeura M, Potter DM, Nikiforova MN, Ferrone S, Jakacki RI, Pollack IF, Okada H. LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res. 2013 Apr 01; 19(7):1816-26. PMID: 23401227; PMCID: PMC3618546.
    37. Yeung JT, Hamilton RL, Okada H, Jakacki RI, Pollack IF. Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy. J Neurooncol. 2013 Jan; 111(2):103-11. PMID: 23179498; PMCID: PMC3546121.
    38. Reinhart B, Mazzacurati L, Forero A, Hong CS, Eguchi J, Okada H, Fellows W, Niranjan A, Cohen JB, Glorioso JC, Grandi P. Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus. Adv Virol. 2012; 2012:815465. PMID: 22924042; PMCID: PMC3424635.
    39. Kohanbash G, Ishikawa E, Fujita M, Ikeura M, McKaveney K, Zhu J, Sakaki M, Sarkar SN, Okada H. Differential activity of interferon-a8 promoter is regulated by Oct-1 and a SNP that dictates prognosis of glioma. Oncoimmunology. 2012 Jul 01; 1(4):487-492. PMID: 22754767.
      View in: PubMed
    40. Martinez Forero I, Okada H, Topalian SL, Gajewski TF, Korman AJ, Melero I. Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med. 2012 May 28; 10:108. PMID: 22640522; PMCID: PMC3404934.
    41. Okada H, Khoury SJ. Type17 T-cells in central nervous system autoimmunity and tumors. J Clin Immunol. 2012 Aug; 32(4):802-8. PMID: 22454247; PMCID: PMC3389562.
    42. Iwami K, Shimato S, Ohno M, Okada H, Nakahara N, Sato Y, Yoshida J, Suzuki S, Nishikawa H, Shiku H, Natsume A, Wakabayashi T. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor a2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy. 2012 Jul; 14(6):733-42. PMID: 22424217.
      View in: PubMed
    43. Zhao X, Bose A, Komita H, Taylor JL, Chi N, Lowe DB, Okada H, Cao Y, Mukhopadhyay D, Cohen PA, Storkus WJ. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol. 2012 Feb 15; 188(4):1782-8. PMID: 22246626; PMCID: PMC3273624.
    44. Kohanbash G, Okada H. Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. Immunol Invest. 2012; 41(6-7):658-79. PMID: 23017140.
      View in: PubMed
    45. Kohanbash G, Okada H. MicroRNAs and STAT interplay. Semin Cancer Biol. 2012 Feb; 22(1):70-5. PMID: 22210182; PMCID: PMC3288787.
    46. Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton RL, Horbinski C, Wang X, Ferrone S, Okada H. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother. 2012 Jun; 61(6):789-801. PMID: 22065046; PMCID: PMC3365630.
    47. Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL. Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res. 2011 Aug; 50(2-3):235-47. PMID: 21717071; PMCID: PMC3695396.
    48. Ma H, Lu C, Ziegler J, Liu A, Sepulveda A, Okada H, Lentzsch S, Mapara MY. Absence of Stat1 in donor CD4? T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J Clin Invest. 2011 Jul; 121(7):2554-69. PMID: 21670504; PMCID: PMC3223821.
    49. Okada H, Pollack IF. Do we need novel radiologic response criteria for brain tumor immunotherapy? Expert Rev Neurother. 2011 May; 11(5):619-22. PMID: 21539483.
      View in: PubMed
    50. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR, Okada H. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 2011 Apr 01; 71(7):2664-74. PMID: 21324923; PMCID: PMC3075086.
    51. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011 Jan 20; 29(3):330-6. PMID: 21149657; PMCID: PMC3056467.
    52. Zhu X, Fujita M, Snyder LA, Okada H. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J Neurooncol. 2011 Aug; 104(1):83-92. PMID: 21116835; PMCID: PMC3068234.
    53. Zhu X, Fallert-Junecko BA, Fujita M, Ueda R, Kohanbash G, Kastenhuber ER, McDonald HA, Liu Y, Kalinski P, Reinhart TA, Salazar AM, Okada H. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother. 2010 Sep; 59(9):1401-9. PMID: 20549206; PMCID: PMC2893267.
    54. Fujita M, Scheurer ME, Decker SA, McDonald HA, Kohanbash G, Kastenhuber ER, Kato H, Bondy ML, Ohlfest JR, Okada H. Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res. 2010 Jul 01; 16(13):3409-19. PMID: 20472682; PMCID: PMC2896455.
    55. Steitz J, Barlow PG, Hossain J, Kim E, Okada H, Kenniston T, Rea S, Donis RO, Gambotto A. A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice. PLoS One. 2010 May 05; 5(5):e10492. PMID: 20463955; PMCID: PMC2864737.
    56. Kalinski P, Okada H. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol. 2010 Jun; 22(3):173-82. PMID: 20409732; PMCID: PMC2892234.
    57. Sasaki K, Kohanbash G, Hoji A, Ueda R, McDonald HA, Reinhart TA, Martinson J, Lotze MT, Marincola FM, Wang E, Fujita M, Okada H. miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. J Transl Med. 2010 Feb 18; 8:17. PMID: 20167088; PMCID: PMC2836279.
    58. Okada H, Kohanbash G, Lotze MT. MicroRNAs in immune regulation--opportunities for cancer immunotherapy. Int J Biochem Cell Biol. 2010 Aug; 42(8):1256-61. PMID: 20144731; PMCID: PMC2889234.
    59. Steitz J, Soloff AC, Barratt-Boyes SM, Alber SM, Watkins SC, Okada H, Gambotto A. Balb/c EGFP mice are tolerant against immunization utilizing recombinant adenoviral-based vectors encoding EGFP: a novel model for the study of tolerance mechanisms and vaccine efficacy. Mol Immunol. 2010 Feb; 47(5):1149-53. PMID: 20022379.
      View in: PubMed
    60. Gardner SL, Ahmed N, Okada H. Immunotherapy for pediatric central nervous system tumors. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S75-81. PMID: 19896544.
      View in: PubMed
    61. Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, McDonald HA, Harper J, Lonning S, Okada H. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res. 2009 Nov 01; 15(21):6551-9. PMID: 19861464; PMCID: PMC2783346.
    62. Sasaki K, Pardee AD, Qu Y, Zhao X, Ueda R, Kohanbash G, Bailey LM, Okada H, Muthuswamy R, Kalinski P, Basse PH, Falo LD, Storkus WJ. IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors. J Immunother. 2009 Oct; 32(8):793-802. PMID: 19752754; PMCID: PMC2796294.
    63. Okada H. Brain tumor immunotherapy with type-1 polarizing strategies. Ann N Y Acad Sci. 2009 Sep; 1174:18-23. PMID: 19769732.
      View in: PubMed
    64. Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze MT, Khan SA, Sobol RW, Okada H. Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A. 2009 Jun 30; 106(26):10746-51. PMID: 19520829; PMCID: PMC2705554.
    65. Komita H, Zhao X, Katakam AK, Kumar P, Kawabe M, Okada H, Braughler JM, Storkus WJ. Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther. 2009 Dec; 16(12):883-91. PMID: 19444303; PMCID: PMC3427922.
    66. Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, McDonald HA, Gibson GA, Watkins SC, Muthuswamy R, Kalinski P, Okada H. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10. Cancer Res. 2009 Feb 15; 69(4):1587-95. PMID: 19190335.
      View in: PubMed
    67. Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, Fujita M. Immunotherapeutic approaches for glioma. Crit Rev Immunol. 2009; 29(1):1-42. PMID: 19348609; PMCID: PMC2713019.
    68. Sasaki K, Pardee AD, Okada H, Storkus WJ. IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. Eur J Immunol. 2008 Oct; 38(10):2865-73. PMID: 18958887; PMCID: PMC2771926.
    69. Sasaki K, Zhao X, Pardee AD, Ueda R, Fujita M, Sehra S, Kaplan MH, Kane LP, Okada H, Storkus WJ. Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo. J Immunol. 2008 Jul 01; 181(1):104-8. PMID: 18566374; PMCID: PMC2596982.
    70. Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J Neurooncol. 2008 Jul; 88(3):245-50. PMID: 18324354; PMCID: PMC2561297.
    71. Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF, Okada H. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol. 2008 Feb 15; 180(4):2089-98. PMID: 18250414.
      View in: PubMed
    72. Ueda R, Low KL, Zhu X, Fujita M, Sasaki K, Whiteside TL, Butterfield LH, Okada H. Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J Transl Med. 2007 Dec 19; 5:68. PMID: 18093336; PMCID: PMC2244605.
    73. Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, Mabold JL, Edington HD, Butterfield LH, Whiteside TL, Potter DM, Schold SC, Pollack IF. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007 Dec 19; 5:67. PMID: 18093335; PMCID: PMC2254376.
    74. Nakamura Y, Watchmaker P, Urban J, Sheridan B, Giermasz A, Nishimura F, Sasaki K, Cumberland R, Muthuswamy R, Mailliard RB, Larregina AT, Falo LD, Gooding W, Storkus WJ, Okada H, Hendricks RL, Kalinski P. Helper function of memory CD8+ T cells: heterologous CD8+ T cells support the induction of therapeutic cancer immunity. Cancer Res. 2007 Oct 15; 67(20):10012-8. PMID: 17942935; PMCID: PMC2905256.
    75. Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, Fujita M, Wesa A, Potter DM, Walker PR, Storkus WJ, Okada H. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res. 2007 Jul 01; 67(13):6451-8. PMID: 17616706.
      View in: PubMed
    76. Berhanu A, Huang J, Watkins SC, Okada H, Storkus WJ. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy. J Immunol. 2007 Mar 15; 178(6):3400-8. PMID: 17339434.
      View in: PubMed
    77. Zhu X, Nishimura F, Sasaki K, Fujita M, Dusak JE, Eguchi J, Fellows-Mayle W, Storkus WJ, Walker PR, Salazar AM, Okada H. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007 Feb 12; 5:10. PMID: 17295916; PMCID: PMC1802742.
    78. MacDonald TJ, Pollack IF, Okada H, Bhattacharya S, Lyons-Weiler J. Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. Methods Mol Biol. 2007; 377:203-22. PMID: 17634619.
      View in: PubMed
    79. Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, Pollack IF, Storkus WJ, Okada H. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses. Cancer Res. 2006 Jun 01; 66(11):5883-91. PMID: 16740728.
      View in: PubMed
    80. Nishimura F, Dusak JE, Eguchi J, Zhu X, Gambotto A, Storkus WJ, Okada H. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res. 2006 Apr 15; 66(8):4478-87. PMID: 16618775.
      View in: PubMed
    81. Sato H, Kuwashima N, Sakaida T, Hatano M, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Okada H. Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. Cancer Gene Ther. 2005 Sep; 12(9):757-68. PMID: 15832173.
      View in: PubMed
    82. Kuwashima N, Nishimura F, Eguchi J, Sato H, Hatano M, Tsugawa T, Sakaida T, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Gambotto A, Pollack IF, Storkus WJ, Okada H. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol. 2005 Aug 15; 175(4):2730-40. PMID: 16081851.
      View in: PubMed
    83. Hatano M, Eguchi J, Tatsumi T, Kuwashima N, Dusak JE, Kinch MS, Pollack IF, Hamilton RL, Storkus WJ, Okada H. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia. 2005 Aug; 7(8):717-22. PMID: 16207473; PMCID: PMC1501889.
    84. Chahlavi A, Daneshvar H, Richmond A, Nishimura F, Okada H, Vogelbaum MA, Barnett GH, Finke J. 895 Desferoxamine Protects T Cells from Glioblastoma Multiforme-mediated Apoptosis and Improves Cytolytic Activity of T Cells in Killing of Tumor Targets. Neurosurgery. 2005 Aug 01; 57(2):428-429. PMID: 28184901.
      View in: PubMed
    85. Eguchi J, Kuwashima N, Hatano M, Nishimura F, Dusak JE, Storkus WJ, Okada H. IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. J Immunol. 2005 Jun 01; 174(11):7194-201. PMID: 15905564.
      View in: PubMed
    86. Okada H. [Immunotherapy for brain tumor: don't get "Lost in Translation"]. No Shinkei Geka. 2005 May; 33(5):433-42. PMID: 15912763.
      View in: PubMed
    87. Witham TF, Okada H, Fellows W, Hamilton RL, Flickinger JC, Chambers WH, Pollack IF, Watkins SC, Kondziolka D. The characterization of tumor apoptosis after experimental radiosurgery. Stereotact Funct Neurosurg. 2005; 83(1):17-24. PMID: 15775705.
      View in: PubMed
    88. Hatano M, Kuwashima N, Tatsumi T, Dusak JE, Nishimura F, Reilly KM, Storkus WJ, Okada H. Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. J Transl Med. 2004 Nov 24; 2(1):40. PMID: 15563374.
      View in: PubMed
    89. Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K, Papworth GD, Watkins SC, Gambotto A, Yoshida J, Pollack IF, Okada H. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Ther. 2004 Nov; 11(21):1551-8. PMID: 15343358.
      View in: PubMed
    90. Okada H, Pollack IF. Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther. 2004 Oct; 4(10):1609-20. PMID: 15461572.
      View in: PubMed
    91. Okada H, Tsugawa T, Sato H, Kuwashima N, Gambotto A, Okada H, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Chambers WH, Potter DM, Storkus WJ, Pollack IF. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res. 2004 Aug 15; 64(16):5830-8. PMID: 15313927.
      View in: PubMed
    92. Okada H. Biologic therapy for brain cancers--based on cellular and immunobiology. Yonsei Med J. 2004 Jun 30; 45 Suppl:68-70. PMID: 15250054.
      View in: PubMed
    93. Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL, Alber SM, Watkins SC, Okada H, Storkus WJ. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res. 2003 Oct 01; 63(19):6378-86. PMID: 14559827.
      View in: PubMed
    94. Witham TF, Villa L, Yang T, Pollack IF, Okada H, Robbins PD, Chambers WH. Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. J Neurooncol. 2003 Aug-Sep; 64(1-2):63-9. PMID: 12952287.
      View in: PubMed
    95. Okada H, Lieberman FS, Edington HD, Witham TF, Wargo MJ, Cai Q, Elder EH, Whiteside TL, Schold SC, Pollack IF. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol. 2003 Aug-Sep; 64(1-2):13-20. PMID: 12952282.
      View in: PubMed
    96. Nakahara N, Pollack IF, Storkus WJ, Wakabayashi T, Yoshida J, Okada H. Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther. 2003 Jul; 10(7):549-58. PMID: 12833135.
      View in: PubMed
    97. Okada H, Kuwashima N. Gene therapy and biologic therapy with interleukin-4. Curr Gene Ther. 2002 Dec; 2(4):437-50. PMID: 12477255.
      View in: PubMed
    98. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res. 2002 Sep; 8(9):2851-5. PMID: 12231526.
      View in: PubMed
    99. Witham TF, Erff ML, Okada H, Chambers WH, Pollack IF. 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery. 2002 Jun; 50(6):1327-34; discussion 1334-5. PMID: 12015852.
      View in: PubMed
    100. Yang T, Witham TF, Villa L, Erff M, Attanucci J, Watkins S, Kondziolka D, Okada H, Pollack IF, Chambers WH. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res. 2002 May 01; 62(9):2583-91. PMID: 11980653.
      View in: PubMed
    101. Nakahara N, Okada H, Witham TF, Attanucci J, Fellows WK, Chambers WH, Niranjan A, Kondziolka D, Pollack IF. Combination of stereotactic radiosurgery and cytokine gene-transduced tumor cell vaccination: a new strategy against metastatic brain tumors. J Neurosurg. 2001 Dec; 95(6):984-9. PMID: 11765844.
      View in: PubMed
    102. Okada H, Villa L, Attanucci J, Erff M, Fellows WK, Lotze MT, Pollack IF, Chambers WH. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther. 2001 Aug; 8(15):1157-66. PMID: 11509946.
      View in: PubMed
    103. Okada H, Pollack IF, Lieberman F, Lunsford LD, Kondziolka D, Schiff D, Attanucci J, Edington H, Chambers W, Kalinski P, Kinzler D, Whiteside T, Elder E, Potter D. Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. Hum Gene Ther. 2001 Mar 20; 12(5):575-95. PMID: 11268289.
      View in: PubMed
    104. Okada H, Attanucci J, Giezeman-Smits KM, Brissette-Storkus C, Fellows WK, Gambotto A, Pollack LF, Pogue-Geile K, Lotze MT, Bozik ME, Chambers WH. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo. Cancer Res. 2001 Mar 15; 61(6):2625-31. PMID: 11289140.
      View in: PubMed
    105. Pollack IF, Okada H, Chambers WH. Exploitation of immune mechanisms in the treatment of central nervous system cancer. Semin Pediatr Neurol. 2000 Jun; 7(2):131-43. PMID: 10914414.
      View in: PubMed
    106. Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Cancer Res. 2000 May 01; 60(9):2449-57. PMID: 10811123.
      View in: PubMed
    107. Okada H, Attanucci J, Tahara H, Pollack IF, Bozik ME, Chambers WH, Lotze MT. Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy. Cancer Gene Ther. 2000 Mar; 7(3):486-94. PMID: 10766355.
      View in: PubMed
    108. Okada H, Pollack IF, Lotze MT, Lunsford LD, Kondziolka D, Lieberman F, Schiff D, Attanucci J, Edington H, Chambers W, Robbins P, Baar J, Kinzler D, Whiteside T, Elder E. Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther. 2000 Mar 01; 11(4):637-53. PMID: 10724042.
      View in: PubMed
    109. Lotze MT, Shurin M, Esche C, Tahara H, Storkus W, Kirkwood JM, Whiteside TL, Elder EM, Okada H, Robbins P. Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity. Cancer J Sci Am. 2000 Feb; 6 Suppl 1:S61-6. PMID: 10685662.
      View in: PubMed
    110. Okada H, Giezeman-Smits KM, Tahara H, Attanucci J, Fellows WK, Lotze MT, Chambers WH, Bozik ME. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther. 1999 Feb; 6(2):219-26. PMID: 10435106.
      View in: PubMed
    111. Okada H. [Neurosurgery and molecular biology: (series 10) gene therapy and biological therapy for brain tumors]. No Shinkei Geka. 1999 Jan; 27(1):9-17. PMID: 10024979.
      View in: PubMed
    112. Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows WK, Lotze MT, Chambers WH, Bozik ME. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer. 1998 Oct 05; 78(2):196-201. PMID: 9754652.
      View in: PubMed
    Hideho's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP